Westphal Nadja, Plicht Björn, Naber Christoph
Klinik für Kardiologie und Angiologie, Elisabeth-Krankhaus, Essen, Germany.
Dtsch Arztebl Int. 2009 Jul;106(28-29):481-9; quiz 490. doi: 10.3238/arztebl.2009.0481. Epub 2009 Jul 13.
Despite important medical advances, infective endocarditis (IE) is still a disease with high morbidity and mortality. Its prophylaxis, diagnosis, and treatment are still a major challenge in clinical practice.
Selective literature review based on the current German and European guidelines and a PubMed search from 2004 onward.
Essential requirements for the rapid diagnosis and specific treatment of IE are the echocardiographic demonstration of endocardial disease and the identification of the causative organism by blood culture. The modified Duke criteria have made the diagnosis more objective but are not a replacement for clinical judgement. It should be borne in mind, when the initial empirical treatment is chosen, that Staphylococcus aureus is currently the most common causative organism. If diagnostic criteria are met that suggest a methicillin-resistant S. aureus infection, then glycopeptide antibiotics are still the standard treatment. Newer agents such as daptomycin can be considered as an alternative, as suggested by recent studies and in view of the increasing frequency of impaired vancomycin susceptibility. Early surgical treatment should be considered for patients who are likely to encounter further complications along their clinical course. According to the current recommendations, antibiotics should be given for endocarditis prophylaxis only to patients about to undergo one of a small number of explicitly defined procedures, who would otherwise be at a high risk of major illness or death. The purpose of this restriction is to make prophylaxis more efficient.
IE remains a potentially lethal infectious disease that can be treated effectively only by physicians from multiple disciplines working in collaboration.
尽管医学取得了重大进展,但感染性心内膜炎(IE)仍然是一种发病率和死亡率很高的疾病。其预防、诊断和治疗在临床实践中仍然是一项重大挑战。
基于当前德国和欧洲指南进行选择性文献综述,并检索2004年以后的PubMed文献。
IE快速诊断和特异性治疗的基本要求是通过超声心动图显示心内膜疾病,并通过血培养鉴定致病微生物。改良的杜克标准使诊断更加客观,但不能替代临床判断。在选择初始经验性治疗时应牢记,金黄色葡萄球菌目前是最常见的致病微生物。如果满足提示耐甲氧西林金黄色葡萄球菌感染的诊断标准,那么糖肽类抗生素仍然是标准治疗药物。根据最近的研究以及万古霉素敏感性受损频率的增加,如达托霉素等新型药物可被视为一种替代药物。对于临床过程中可能会遇到进一步并发症的患者,应考虑早期手术治疗。根据当前建议,仅应对即将接受少数明确界定手术之一的患者进行心内膜炎预防用药,否则这些患者将面临重大疾病或死亡的高风险。这种限制的目的是提高预防的有效性。
IE仍然是一种潜在致命的传染病,只有多学科医生合作才能有效治疗。